Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma

被引：23
|
作者：
Girgis, Suzette [1 ,3 ]
Lin, Shun Xin Wang [1 ]
Pillarisetti, Kodandaram [1 ]
Verona, Raluca [1 ]
Vieyra, Diego [1 ]
Casneuf, Tineke [2 ]
Fink, Damien [1 ]
Miao, Xin [1 ]
Chen, Yang [1 ]
Stephenson, Tara [1 ]
Banerjee, Arnob [1 ]
Hilder, Brandi W. [1 ]
Russell, Jeffery [1 ]
Infante, Jeffrey [1 ]
Elsayed, Yusri [1 ]
Smit, Jennifer [1 ]
Goldberg, Jenna D. [1 ]
机构：
[1] Janssen Res & Dev LLC, Spring House, PA USA
[2] Janssen Res & Dev LLC, Beerse, Belgium
[3] Janssen Res & Dev, 920 Route 202, Raritan, NJ 08869 USA
来源：
BLOOD ADVANCES | 2023年 / 7卷 / 04期
关键词：
CELL MATURATION ANTIGEN; BONE-MARROW; SURVIVAL;
D O I：
10.1182/bloodadvances.2022007625
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：644 / 648
页数：5
相关论文
共 50 条
  • [41] Real-World Evaluation of Teclistamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)
    Asoori, Sireesha
    Popat, Rakesh
    Martinez-Lopez, Joaquin
    Kastritis, Efstathios
    Brunaldi, Larissa
    Bansal, Radhika
    Corraes, Andre De Menezes Silva
    Yong, Kwee
    Mactier, Catriona
    Corona, Magdalena
    Saez Marin, Adolfo Jesus
    Fotiou, Despina
    Dimopoulos, Meletios Athanasios
    Chhabra, Saurabh
    Ailawadhi, Sikander
    Parrondo, Ricardo
    Martin, Thomas
    Durie, Brian G. M.
    Lin, Yi
    BLOOD, 2023, 142
  • [42] Talquetamab plus Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Updated TRIMM-2 Results
    Dholaria, Bhagirathbhai
    Weisel, Katja
    Mateos, Maria-Victoria
    Goldschmidt, Harmut
    Martin, Thomas
    Morillo, Daniel
    Reece, Donna
    Rodriguez-Otero, Paula
    Bhutani, Manisha
    D'Souza, Anita
    Oriol, Albert
    Rosinol, Laura
    Bahlis, Nizar
    Bakshi, Kalpana
    Kang, Lijuan
    Vandenberk, Lien
    Smit, M. Damiette
    Wasch, Ralph
    van de Donk, Niels
    Chari, Ajai
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S476 - S477
  • [43] Phase 1b Results for Subcutaneous Talquetamab Plus Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma
    Chari, Ajai
    Hari, Parameswaran
    Bahlis, Nizar J.
    Mateos, Maria-Victoria
    van de Donk, Niels W. C. J.
    Dholaria, Bhagirathbhai
    Garfall, Alfred L.
    Goldschmidt, Hartmut
    Kortuem, K. Martin
    Krishnan, Amrita Y.
    Martin, Thomas
    Morillo Gilles, Daniel
    Oriol, Albert
    Reece, Donna E.
    Rodriguez, Cesar
    Rodriguez-Otero, Paula
    San-Miguel, Jesus F.
    Usmani, Saad Z.
    Verona, Raluca I.
    Lin, Shun Xin Wang
    Prior, Thomas J.
    Wade, Mark
    Weiss, Brendan M.
    Goldberg, Jenna D.
    Askari, Elham
    BLOOD, 2021, 138
  • [44] Real-World Safety and Efficacy of Talquetamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma
    Shaikh, Hira
    Lochner, Jonathan
    Friend, Reed
    Snyder, Jordan
    Davis, James
    Patrus, Gina
    Dileo, Rachel
    Ahmed, Nausheen
    Mewawalla, Prerna
    Poonsombudlert, Kittika
    Struble, Emily
    Wolcott, Allyson
    Green, Kimberly
    Sparrow, Samantha
    Mushtaq, Muhammad Umair
    Paul, Barry
    Abdallah, Al-Ola
    Strouse, Christopher
    Hashmi, Hamza
    Atrash, Shebli
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S87 - S88
  • [45] The adverse effects of thalidomide in relapsed and refractory patients of multiple myeloma
    Grover, JK
    Uppal, G
    Raina, V
    ANNALS OF ONCOLOGY, 2002, 13 (10) : 1636 - 1640
  • [46] Real-World Safety and Early Efficacy of Talquetamab in Patients with Heavily-Pretreated Relapsed/Refractory Multiple Myeloma
    Costa, Bruno
    Tan, Carlyn
    Shekarkhand, Tala
    Firestone, Ross
    Jurgens, Eric
    Miller, Kevin
    Lesokhin, Alexander
    Shah, Gunjan
    Korde, Neha
    Rajeeve, Sridevi
    Chung, David
    Landau, Heather
    Scordo, Michael
    Hassoun, Hani
    Maclachlan, Kylee
    Shah, Urvi
    Hultcrantz, Malin
    Hamadeh, Issam
    Giralt, Sergio
    Mailankody, Sham
    Usmani, Saad
    Hashmi, Hamza
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S46 - S47
  • [47] Real-World Safety and Efficacy of Teclistamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma
    Dima, Danai
    Davis, James A.
    Ahmed, Nausheen
    Sannareddy, Aishwarya
    Shaikh, Hira
    Mahmoudjafari, Zahra
    Khouri, Jack
    Kaur, Gurbakhash
    Strouse, Christopher
    Valent, Jason
    Larry, Anderson D., Jr.
    Anwer, Faiz
    Abdallah, Al-Ola
    Hashmi, Hamza
    BLOOD, 2023, 142
  • [48] Population pharmacokinetics of belantamab mafodotin, a BCMA-targeting agent in patients with relapsed/refractory multiple myeloma
    Rathi, Chetan
    Collins, Jon
    Struemper, Herbert
    Opalinska, Joanna
    Jewell, Roxanne C.
    Ferron-Brady, Geraldine
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2021, 10 (08): : 851 - 863
  • [49] Therapy for Patients with relapsed and/or refractory multiple Myeloma New Data on BCMA-directed therapeutic Approaches
    Rudesheim, Sabine M.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (04) : 212 - 212
  • [50] Brazilian Relapsed Refractory Multiple Myeloma Patients Treated with Teclistamab Outside of Clinical Trials as an Expanded Access Program
    Pericole, Fernando
    Lima, Juliana Souza
    Ottoni, Erica
    Ribeiro, Glaciano
    Crusoe, Edvan de Queiroz
    Cunha, Rafael
    Costa, Abel
    Cury, Priscilla
    Maciel, James
    Hungria, Vania T. M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S196 - S197
12345